This website for the UK public is developed and funded by AstraZeneca as part of a disease awareness campaign. It is for information only, not for diagnosis. If you are concerned about symptoms, please see your GP or another healthcare professional.

Your Portuguese heritage is a big part of who 
you are

Could ATTRv amyloidosis be too?

This website is for those with Portuguese heritage who may be at risk of hereditary transthyretin amyloidosis (ATTRv). It can also be used by people who have been diagnosed with the condition who have the V50M mutation. For more information on other types of ATTR amyloidosis, visit Amyloidosis UK.

Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a rare but serious condition that can cause life-limiting symptoms.

ATTRv amyloidosis can be caused by a fault in a person's genes called the 'V50M mutation'. This type of ATTRv amyloidosis is also known as 'Doença dos Pezinhos', or 'little feet disease'. The gene mutation can be passed down through families and is more common in those from Portugal. For example, about 1 in 538 people with heritage from the North of Portugal are thought to be carriers of the V50M mutation.

If you have Portuguese heritage, you and your family might be at risk. But you are in the right place. Here you can read more about the condition, find out what symptoms to look out for and learn when to seek help.

thumbnail thumbnail

Finding support

Whether you are just learning about ATTRv amyloidosis or supporting a friend or family member with the condition, there is lots of help and information available. Practical resources, support groups and symptom education can help you take your next step.

image image

If you have any feedback on this resource, please fill in our questionnaire by clicking here.

  1. Amyloidosis Research Consortium. Disease Overview: Hereditary Transthyretin Amyloidosis. Available at: https://arci.org/wp-content/uploads/2025/10/WEB-Booklet-1_hATTR_05052022-RC-1.pdf. Accessed August 2026.
  2. Coelho S. Big feat solving Little Feet’s. iSGTW. 2011. Accessed August 2026.
  3. Obi CA, Mostertz WC, Griffin JM, et al. Methodist DeBakey Cardiovasc J. 2022;18(2):17–26.

GB-77623 | August 2026 | To be reviewed August 2028